Your session is about to expire
← Back to Search
BMS-986278 for Pulmonary Fibrosis
Study Summary
This trial tests the effectiveness, safety and tolerability of a new drug for people with progressive pulmonary fibrosis.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Does BMS-986278 Dose 1 provide a safe treatment option for patients?
"Prior clinical evidence offers assurance that BMS-986278 Dose 1 is safe, thus attaining a 3 on our safety scale. This data is derived from Phase 3 trials which demonstrate efficacy and multiple rounds of supporting research."
In what specific locales is this clinical experiment taking place?
"This clinical trial is being conducted at 8 different locations, including University Hospitals Cleveland Medical Center in Cleveland, Local Institution - 0110 in Aarhus, and Local Institution - 0258 in Mainz. Additionally, there are 5 other recruiting sites across the world."
Is this clinical trial actively seeking participants?
"The most recent update posted on clinicaltrials.gov indicates that this particular study is no longer recruiting participants, despite initially being posted on September 18th 2023. Fortunately, there are a plethora of other medical trials actively looking for individuals to join their studies right now; 433 to be exact."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger